NRX Pfcf Ratio vs Free Cash Flow Yield Analysis

NRXP Stock

USD 1.18 0.03 2.48%

NRX Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NRX Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NRX Pharmaceuticals is a good investment. Please check the relationship between NRX Pharmaceuticals Pfcf Ratio and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRX Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

Pfcf Ratio vs Free Cash Flow Yield

Pfcf Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NRX Pharmaceuticals Pfcf Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between NRX Pharmaceuticals' Pfcf Ratio and Free Cash Flow Yield is -0.15. Overlapping area represents the amount of variation of Pfcf Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of NRX Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NRX Pharmaceuticals' Pfcf Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pfcf Ratio of NRX Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Pfcf Ratio i.e., NRX Pharmaceuticals' Pfcf Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.15

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Pfcf Ratio

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from NRX Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NRX Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRX Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.As of 12/11/2024, Selling General Administrative is likely to grow to about 20.3 M, while Issuance Of Capital Stock is likely to drop slightly above 8.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	94.4M	44.4M	27.6M	32.9M
Cost Of Revenue	2K	4K	5K	4.8K

Total Operating Expenses Cost Of Revenue

NRX Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Long Term Debt	Non Current Liabilities Total	Net Tangible Assets	Other Assets	Net Receivables
Total Assets		-0.67	-0.83	0.98	0.08	0.83	-0.88	-0.46	0.96	-0.6	-0.46	0.97	-0.52	0.97	0.91	-0.47	-0.79	-0.84	-0.49	0.97	-0.68	-0.94	-0.1	-0.01	0.79	0.7
Other Current Liab	-0.67		0.95	-0.78	-0.09	-0.35	0.57	0.16	-0.6	0.11	0.16	-0.6	0.47	-0.6	-0.62	0.1	0.23	0.94	0.17	-0.6	0.1	0.55	-0.02	-0.62	-0.58	-0.13
Total Current Liabilities	-0.83	0.95		-0.91	-0.11	-0.6	0.77	0.32	-0.79	0.3	0.32	-0.78	0.59	-0.78	-0.82	0.32	0.49	1.0	0.34	-0.78	0.37	0.76	0.0	-0.41	-0.75	-0.4
Total Stockholder Equity	0.98	-0.78	-0.91		0.09	0.79	-0.87	-0.43	0.94	-0.52	-0.43	0.94	-0.56	0.94	0.91	-0.45	-0.72	-0.92	-0.46	0.94	-0.61	-0.92	-0.07	0.12	0.81	0.63
Net Debt	0.08	-0.09	-0.11	0.09		0.27	-0.33	-0.84	0.32	0.28	-0.84	0.31	-0.71	0.31	0.38	-0.53	-0.31	-0.11	-0.82	0.31	0.13	-0.33	-0.92	-0.4	-0.31	0.4
Retained Earnings	0.83	-0.35	-0.6	0.79	0.27		-0.88	-0.71	0.9	-0.68	-0.71	0.89	-0.62	0.9	0.91	-0.73	-0.99	-0.61	-0.74	0.89	-0.85	-0.88	-0.17	-0.45	0.72	0.96
Accounts Payable	-0.88	0.57	0.77	-0.87	-0.33	-0.88		0.61	-0.91	0.53	0.61	-0.9	0.58	-0.91	-0.96	0.49	0.83	0.76	0.64	-0.9	0.58	0.94	0.25	0.2	-0.62	-0.8
Cash	-0.46	0.16	0.32	-0.43	-0.84	-0.71	0.61		-0.68	0.14	1.0	-0.67	0.84	-0.67	-0.7	0.84	0.75	0.32	1.0	-0.67	0.42	0.66	0.76	0.59	-0.16	-0.81
Non Current Assets Total	0.96	-0.6	-0.79	0.94	0.32	0.9	-0.91	-0.68		-0.52	-0.68	1.0	-0.7	1.0	0.97	-0.65	-0.87	-0.8	-0.71	1.0	-0.69	-0.98	-0.32	-0.18	0.7	0.82
Non Currrent Assets Other	-0.6	0.11	0.3	-0.52	0.28	-0.68	0.53	0.14	-0.52		0.14	-0.51	-0.05	-0.52	-0.48	0.17	0.67	0.29	0.16	-0.51	0.7	0.49	-0.33	0.33	-0.6	-0.62
Cash And Short Term Investments	-0.46	0.16	0.32	-0.43	-0.84	-0.71	0.61	1.0	-0.68	0.14		-0.67	0.84	-0.67	-0.7	0.84	0.75	0.32	1.0	-0.67	0.42	0.66	0.76	0.59	-0.16	-0.81
Common Stock Total Equity	0.97	-0.6	-0.78	0.94	0.31	0.89	-0.9	-0.67	1.0	-0.51	-0.67		-0.68	1.0	0.96	-0.64	-0.86	-0.79	-0.7	1.0	-0.68	-0.98	-0.32	-0.18	0.69	0.81
Common Stock Shares Outstanding	-0.52	0.47	0.59	-0.56	-0.71	-0.62	0.58	0.84	-0.7	-0.05	0.84	-0.68		-0.68	-0.75	0.87	0.6	0.6	0.86	-0.68	0.4	0.69	0.59	0.14	-0.39	-0.61
Short Term Investments	0.97	-0.6	-0.78	0.94	0.31	0.9	-0.91	-0.67	1.0	-0.52	-0.67	1.0	-0.68		0.96	-0.64	-0.87	-0.79	-0.7	1.0	-0.69	-0.98	-0.32	-0.18	0.7	0.81
Capital Surpluse	0.91	-0.62	-0.82	0.91	0.38	0.91	-0.96	-0.7	0.97	-0.48	-0.7	0.96	-0.75	0.96		-0.67	-0.86	-0.83	-0.73	0.96	-0.66	-0.98	-0.3	-0.16	0.7	0.82
Other Current Assets	-0.47	0.1	0.32	-0.45	-0.53	-0.73	0.49	0.84	-0.65	0.17	0.84	-0.64	0.87	-0.64	-0.67		0.76	0.34	0.86	-0.64	0.7	0.64	0.46	0.49	-0.45	-0.79
Other Stockholder Equity	-0.79	0.23	0.49	-0.72	-0.31	-0.99	0.83	0.75	-0.87	0.67	0.75	-0.86	0.6	-0.87	-0.86	0.76		0.5	0.78	-0.86	0.86	0.86	0.24	0.57	-0.64	-0.99
Total Liab	-0.84	0.94	1.0	-0.92	-0.11	-0.61	0.76	0.32	-0.8	0.29	0.32	-0.79	0.6	-0.79	-0.83	0.34	0.5		0.35	-0.79	0.39	0.77	0.01	-0.41	-0.76	-0.41
Total Current Assets	-0.49	0.17	0.34	-0.46	-0.82	-0.74	0.64	1.0	-0.71	0.16	1.0	-0.7	0.86	-0.7	-0.73	0.86	0.78	0.35		-0.7	0.46	0.69	0.73	0.58	-0.2	-0.83
Common Stock	0.97	-0.6	-0.78	0.94	0.31	0.89	-0.9	-0.67	1.0	-0.51	-0.67	1.0	-0.68	1.0	0.96	-0.64	-0.86	-0.79	-0.7		-0.68	-0.98	-0.32	-0.18	0.69	0.81
Short Long Term Debt Total	-0.68	0.1	0.37	-0.61	0.13	-0.85	0.58	0.42	-0.69	0.7	0.42	-0.68	0.4	-0.69	-0.66	0.7	0.86	0.39	0.46	-0.68		0.67	-0.15	0.42	-0.81	-0.81
Long Term Debt	-0.94	0.55	0.76	-0.92	-0.33	-0.88	0.94	0.66	-0.98	0.49	0.66	-0.98	0.69	-0.98	-0.98	0.64	0.86	0.77	0.69	-0.98	0.67		0.34	0.2	-0.67	-0.81
Non Current Liabilities Total	-0.1	-0.02	0.0	-0.07	-0.92	-0.17	0.25	0.76	-0.32	-0.33	0.76	-0.32	0.59	-0.32	-0.3	0.46	0.24	0.01	0.73	-0.32	-0.15	0.34		0.42	0.4	-0.32
Net Tangible Assets	-0.01	-0.62	-0.41	0.12	-0.4	-0.45	0.2	0.59	-0.18	0.33	0.59	-0.18	0.14	-0.18	-0.16	0.49	0.57	-0.41	0.58	-0.18	0.42	0.2	0.42		0.17	-0.66
Other Assets	0.79	-0.58	-0.75	0.81	-0.31	0.72	-0.62	-0.16	0.7	-0.6	-0.16	0.69	-0.39	0.7	0.7	-0.45	-0.64	-0.76	-0.2	0.69	-0.81	-0.67	0.4	0.17		0.53
Net Receivables	0.7	-0.13	-0.4	0.63	0.4	0.96	-0.8	-0.81	0.82	-0.62	-0.81	0.81	-0.61	0.81	0.82	-0.79	-0.99	-0.41	-0.83	0.81	-0.81	-0.81	-0.32	-0.66	0.53

Click cells to compare fundamentals

NRX Pharmaceuticals Account Relationship Matchups

NRX Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	32.1M	2.9M	32.7M	25.8M	7.3M	6.9M
Other Current Liab	7.6K	42.7M	7.7M	5.8M	5.3M	9.7M
Total Current Liabilities	622.4K	46.2M	11.9M	16.6M	19.0M	14.9M
Total Stockholder Equity	29.5M	(43.8M)	20.8M	7.4M	(11.7M)	(11.1M)
Net Debt	2.0M	(1.1M)	(27.1M)	(9.5M)	4.6M	4.8M
Retained Earnings	369.5K	(90.2M)	(183.2M)	(223.1M)	(253.1M)	(240.5M)
Accounts Payable	622.4K	3.2M	3.7M	2.1M	4.6M	2.3M
Cash	6.0	1.9M	27.6M	20.1M	4.6M	8.6M
Non Current Assets Total	32.0M	11K	15K	21K	431K	409.5K
Non Currrent Assets Other	1.0	11K	15K	21K	431K	452.6K
Cash And Short Term Investments	6.0	1.9M	27.6M	20.1M	4.6M	8.6M
Common Stock Shares Outstanding	508.8K	34.3M	46.9M	65.8M	7.6M	7.2M
Liabilities And Stockholders Equity	32.1M	2.9M	32.7M	25.8M	7.3M	6.9M
Other Current Assets	69.5K	240K	5.1M	11.5M	2.3M	3.0M
Other Stockholder Equity	29.1M	46.4M	204.0M	230.3M	241.3M	253.4M
Total Liab	2.6M	46.7M	11.9M	18.4M	19.0M	15.7M
Total Current Assets	69.5K	2.9M	32.7M	25.8M	6.9M	10.8M
Common Stock	24.5M	43K	59K	67K	84K	79.8K
Short Long Term Debt Total	2.0M	797K	518K	10.5M	9.2M	9.6M

Pair Trading with NRX Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with NRX Stock

0.67	VALN	Valneva SE ADR	Pair Corr
0.67	ERNA	Eterna Therapeutics	Pair Corr

Moving against NRX Stock

0.77	BMY	Bristol Myers Squibb	Pair Corr
0.76	GILD	Gilead Sciences	Pair Corr
0.64	ESPR	Esperion Therapeutics	Pair Corr
0.45	DNA	Ginkgo Bioworks Holdings	Pair Corr
0.44	FLGC	Flora Growth Corp	Pair Corr

The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.

The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC